Slides on Key Decisions in HIV Care: Switching to Long-acting ART

See key clinical trial data and practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure.
Daniel R. Kuritzkes, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 529 KB
Released: June 4, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Large, retrospective analysis supports the effectiveness and safety of dolutegravir-based regimens among children and adolescents, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 22, 2021

Post-hoc analysis of TANGO assessed changes in quantitative and qualitative viral load through Week 96 and inflammatory biomarkers from baseline to Week 96, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 22, 2021

Lenacapavir, in combination with an optimized background regimen, showed favorable efficacy and safety in patients with MDR HIV-1 infection from IAS 2021, as reported by Clinical Care Options (CCO).

Released: July 22, 2021

Dr Adeeba Kamarulzaman previews 11th IAS Conference on HIV Science, with official coverage and analysis from Clinical Care Options (CCO)

Adeeba Kamarulzaman, MBBS, FRACP, FAMM, FASc Released: July 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue